ATAD 3A and ATAD 3B are distal 1p-located genes differentially expressed in human glioma cell lines and present in vitro anti-oncogenic and chemoresistant properties

Experimental Cell Research

Volumn 314, Issue 15, 2008, Pages 2870-2883

  Hubstenberger, Arnaud ^a   Labourdette, Gérard ^b   Baudier, Jacques ^a   Rousseau, Denis ^a  

^a CEA GRENOBLE   (France)

^b CENTRE DE NEUROCHIMIE   (France)

Author keywords

ATAD 3; Chemoresistance; Doxorubicin; Glioma; Oligodendroglioma; S100b

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; NOCODAZOLE; PEPTIDE ANTIBODY; PROTEIN S100B;

ANIMAL CELL; ARTICLE; ASTROCYTOMA CELL; ATAD 3A GENE; ATAD 3B GENE; BRAIN CORTEX; CELL CYCLE PHASE; CELL STRAIN 3T3; CELL STRAIN COS1; CELL SURVIVAL; CELL TRANSFORMATION; CLONOGENESIS; CONTROLLED STUDY; EMBRYONAL TISSUE; GENE; GENE EXPRESSION; GENE FUNCTION; GENE LOCATION; GENETIC ANALYSIS; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NONHUMAN; OLIGODENDROGLIOMA; PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 50249171832     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2008.06.017     Document Type: Article

References (51)

1. Ashby L.S., and Shapiro W.R. Low-grade glioma: supratentorial astrocytoma, oligodendroglioma, and oligoastrocytoma in adults. Curr. Neurol. Neurosci. Rep. 4 3 (2004) 211-217
2. Mischel P.S., Cloughesy T.F., and Nelson S.F. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat. Neurosci. 5 (2004) 782-792
3. Cairncross J.G., Ueki K., Zlatescu M.C., Lisle D.K., Finkelstein D.M., Hammond R.R., Silver J.S., Stark P.C., Macdonald D.R., Ino Y., Ramsay D.A., and Louis D.N. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer Inst. 90 19 (1998) 1473-1479
4. Paleologos N.A., Macdonald D.R., Vick N.A., and Cairncross J.G. Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology 53 5 (1999) 1141-1143
5. Van den Bent M.J. Advances in the biology and treatment of oligodendrogliomas. Curr. Opin. Neurol. 17 6 (2004) 675-680
6. Gupta M., Djalilvand A., and Brat D.J. Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma. Am. J. Clin. Pathol. 124 5 (2005) 755-768
7. Sallinen S.L., Sallinen P.K., Haapasalo H.K., Helin H.J., Helen P.T., Schraml P., Kallioniemi O.P., and Kononen J. Identification of differentially expressed genes in human glioma by DNA microarray and tissue chip techniques. Cancer Res. 60 (2000) 6617-6622
8. Mischel P.S., Shai R., Shi T., Horvath S., Lu K.V., Choe G., Seligson D., Kremen T.J., Palotie A., Liau L.M., Cloughesy T.F., and Nelson S.F. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 22 15 (2003) 2361-2373
9. Nutt C.L., Mani D.R., Betensky R.A., Tamayo P., Cairncross J.G., Ladd C., Pohl U., Hartmann C., McLaughlin M.E., Batchelor T.T., Black P.M., von Deimling A., Pomeroy S.L., Golub T.R., and Louis D.N. Gene expression-based classification of malignant glioma correlates better with survival than histological classification. Cancer Res. 63 (2003) 1602-1607
10. Shai R., Shi T., Kremen J., Horvath S., Liau L.M., Cloughesy T.F., Mischel P.S., and Nelson S.F. Gene expression profiling identifies molecular subtypes of glioma. Oncogene 22 (2003) 4918-4923
11. French P.J., Swagemakers S.M.A., Nagel J.H.A., Kouwenhoven M.C.M., Brouwer E., van der Spek P., Luider T.M., Kros J.M., van den Bent M.J., and Sillevis Smitt P.A. Gene expression profiles associated with treatment response in oligodendroglioma. Cancer Res. 65 (2005) 11335-11344
12. Fuller G.N., Hess K.R., Rhee C.H., Yung W.K., Sawaya R.A., Bruner J.M., and Zhang W. Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol. 12 1 (2002) 108-116
13. Rich J.N., Hans C., Jones B., Iversen E.S., McLendon R.E., Rasheed B.K., Dobra A., Dressman H.K., Bigner D.D., Nevins J.R., and West M. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res. 65 10 (2005) 4051-4058
14. Smith J.S., Alderete B., Minn Y., Borell T.J., Perry A., Mohapatra G., Mohapatra G., Hosek S.M., Kimmel D., O'Fallon J., Yates A., Feuerstein B.G., Burger P.C., Scheithauer B.W., and Jenkins R.B. Localization of common deletion regions on 1p and 19q in human glioma and their association with histological subtype. Oncogene 18 (1999) 4144-4152
15. Mukaza A., Ueki K., Matsumoto S., Tsutsumi S., Nishikawa R., Fujimaki T., Asai A., Kirino T., and Aburatani H. Distinction in gene expression profiles of oligodendroglioma with and without allelic loss of 1p. Oncogene 21 (2002) 3961-3968
16. Huang H., Okamoto Y., Yokoo H., Heppner F.L., Vital A., Fevre M., Jouvet A., Yonekawa Y., Lazaridis E.N., Kleihues P., and Ohgaki H. Gene expression profiling and subgroup identification of oligodendroglioma. Oncogene 23 (2004) 6012-6022
17. Dong Z., Pang J.C.S., Ng M.H., Poon W.S., Zhou L., and Ng H.K. Identification of two contiguous minimally deleted regions on chromosome 1p36.31-1p36.32 in oligodendroglial tumours. British J. of Cancer 91 (2004) 1105-1111
18. McDonald J.M., See S.J., Tremont I.W., Colman H., Gilbert M.R., Groves M., Burger P.C., Louis D.N., Giannini C., Fuller G., Passe S., Blair H., Jenkins R.B., Yang H., Ledoux A., Aaron J., Tipnis U., Zhang W., Hess K., and Aldape K. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 104 7 (2005) 1468-1477
19. Ohgaki H., and Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol. 64 6 (2005) 479-489
20. Stupp R., Hegi M.E., van den Bent M.J., Mason W.P., Weller M., Mirimanoff R.O., and Cairncross J.G. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist 11 2 (2006) 165-180
21. Dong S., Pang J.C., Hu J., Zhou L.F., and Ng H.K. Transcriptional inactivation of TP73 expression in oligodendroglial tumors. Int. J. Cancer 98 3 (2002) 370-375
22. Tews B., Felsberg J., Hartmann C., Kunitz A., Hahn M., Toedt G., Neben K., Hummerich L., von Deimling A., Reifenberger G., and Lichter P. Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. Int. J. Cancer 119 4 (2006) 792-800
23. Barbashina V., Salazar P., Holland E.C., Rosenblum M.K., and Ladanyi M. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin. Cancer Res. 11 3 (2005) 1119-1128
24. Wolf R.M., Draghi N., Liang X., Dai C., Uhrbom L., Eklof C., Westermark B., Holland E.C., and Resh M.D. p190RhoGAP can act to inhibit PDGF-induced gliomas in mice: a putative tumor suppressor encoded on human chromosome 19q13.3. Genes Dev. 17 4 (2003) 476-487
25. Ueki K., Nishikawa R., Nakazato Y., Hirose T., Hirato J., Funada N., Fujimaki T., Hojo S., Kubo O., Ide T., Usui M., Ochiai C., Ito S., Takahashi H., Mukasa A., Asai A., and Kirino T. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin. Cancer Res. 8 1 (2002) 196-201
26. Fallon K.B., Palmer C.A., Roth K.A., Nabors L.B., Wang W., Carpenter M., Banerjee R., Forsyth P., Rich K., and Perry A. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J. Neuropathol. Exp. Neurol. 63 4 (2004) 314-322
27. Ikura M., and Ames J.B. Genetic polymorphism and protein conformational plasticity in the calmodulin superfamily: two ways to promote multifunctionality. Proc. Natl. Acad. Sci. U. S. A. 103 5 (2006) 1159-1164
28. Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G., Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D., Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K., Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F., Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L., Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E., Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C., Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J., Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H., Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W., Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S., Sanchez A., Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G., Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S., Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E., Jones S.J., and Marra M.A. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 16899-16903
29. Geuijen C.A., Bijl N.B., Smit C.M., Cox F., Throsby M., Visser T.J., Jongeneelen M.A., Bakker A.B., Kruisbeek A.M., Goudsmit J., and de Kruif J. A proteomic approach to target identification using phage display. Eur. J. of Cancer 41 (2005) 178-187
30. Schaffrik M., Mack B., Matthias C., Rauch J., and Gires O. Molecular characterization of the tumor-associated antigen AAA-TOB3. Cell Mol Life Sci. 63 18 (2006) 2162-2174
31. Hanson P.I., and Whiteheart S.W. AAA+ proteins: have engine, will work. Nat. Rev. Mol. Cell Biol. 6 7 (2005) 519-529
32. Cordin O., Banroques J., Tanner N.K., and Linder P. The DEAD-box protein family of RNA helicases. Gene 367 (2006) 17-37
33. Branle F., Lefranc F., Camby I., Jeuken J., Geurts-Moespot A., Sprenger S., Sweep F., Kiss R., and Salmon I. Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer 95 3 (2002) 641-655
34. Carbajo S., Hernandez J.L., and Carbajo-Perez E. Proliferative activity of cells of the intermediate lobe of the rat pituitary during the postnatal period. Tissue Cell. 24 6 (1992) 829-834
35. Lepore D.A., Roeszler K., Wagner J., Ross S.A., Bauer K., and Thomas P.Q. Identification and enrichment of colony-forming cells from the adult murine pituitary. Exp. Cell Res. 308 1 (2005) 166-176
36. Simmons D.M., Voss J.W., Ingraham H.A., Holloway J.M., Broide R.S., Rosenfeld M.G., and Swanson L.W. Pituitary cell phenotypes involve cell-specific Pit-1 mRNA translation and synergistic interactions with other classes of transcription factors. Genes Dev. 4 5 (1990) 695-711
37. Sassoon D., Lyons G., Wright W.E., Lin V., Lassar A., Weintraub H., and Buckingham M. Expression of two myogenic regulatory factors myogenin and MyoD1 during mouse embryogenesis. Nature 341 6240 (1989) 303-307
38. Hinterberger T.J., Sassoon D.A., Rhodes S.J., and Konieczny S.F. Expression of the muscle regulatory factor MRF4 during somite and skeletal myofiber development. Dev. Biol. 147 1 (1991) 144-156
39. Pownall M.E., Gustafsson M.K., and Emerson Jr. C.P. Myogenic regulatory factors and the specification of muscle progenitors in vertebrate embryos. Annu. Rev. Cell Dev. Biol. 18 (2002) 747-783
40. Zeller K.I., Jegga A.G., Aronow B.J., O'Donnell K.A., and Dang C.V. An integrated data base of genes responsive to the Myc oncoprotein. Genome Biol. 4 (2003) R69
41. Gires O., Münz M., Schaffrick M., Kieu C., Rauch J., Ahlemann M., Eberle D., Mack B., Wollenberg B., Lang S., Hofmann T., Hammerschmidt W., and Zeidler R. Profile identification of disease-associated humoral antigen using AMIDA. Cell. & Mol. Sciences 61 (2004) 1198-1207
42. He J., Mao C.C., Reyes A., Sembongi H., Di Re M., Granycome C., Clippingdale A.B., Fearnley I.M., Harbour M., Robinson A.J., Reichelt S., Spelbrink J.N., Walker J.E., and Holt I.J. The AAA+ protein ATAD3 has displacement loop binding properties and is involved in mitochondrial nucleoid organization. J Cell Biol. 176 2 (2007) 141-146
43. Trent J., Meltzer P., Rosenblum M., Harsh G., Kinzler K., Mashal R., Feinberg A., and Vogelstein B. Evidence for rearrangement, amplification, and expression of c-myc in a human glioblastoma. Proc. Natl. Acad. Sci. U S A. 83 2 (1986) 470-473
44. Da Cruz S., Xenarios I., Langridge J., Vilbois F., Parone P.A., and Martinou J.C. Proteomic analysis of the mouse liver mitochondrial inner membrane. J. Biol. Chem. 278 42 (2003) 41566-41571
45. Bogenhagen D.F., Rousseau D., and Burke S. The layered structure of human mitochondrial DNA nucleoids. J. Biol. Chem. 283 6 (2008) 3665-3667
46. Heilstedt H.A., Ballif B.C., Howard L.A., Lewis R.A., Stal S., Kashork C.D., Bacino C.A., Shapira S.K., and Shaffer L.G. Physical map of 1p36, placement of breakpoints in monosomy 1p36, and clinical characterization of the syndrome. Am. J. Hum. Genet. 72 5 (2003) 1200-1212
47. Van Noesel M.M., and Versteeg R. Pediatric neuroblastomas: genetic and epigenetic 'danse macabre'. Gene 325 (2004) 1-15
48. Thompson F.H., Taetle R., Trent J.M., Liu Y., Massey-Brown K., Scott K.M., Weinstein R.S., Emerson J.C., Alberts D.S., and Nelson M.A. Band 1p36 abnormalities and t(1;17) in ovarian carcinoma. Cancer Genet. Cytogenet. 96 2 (1997) 106-110
49. Nelson M.A., Radmacher M.D., Simon R., Aickin M., Yang J., Panda L., Emerson J., Roe D., Adair L., Thompson F., Bangert J., Leong S.P., Taetle R., Salmon S., and Trent J. Chromosome abnormalities in malignant melanoma: clinical significance of nonrandom chromosome abnormalities in 206 cases. Cancer Genet. Cytogenet. 122 2 (2000) 101-109
50. Buckley P.G., Jarbo C., Menzel U., Mathiesen T., Scott C., Gregory S.G., Langford C.F., and Dumanski J.P. Comprehensive DNA copy number profiling of meningioma using a chromosome 1 tiling path microarray identifies novel candidate tumor suppressor loci. Cancer Res. 65 7 (2005) 2653-2661
51. Mora J., Cheung N.K., Kushner B.H., LaQuaglia M.P., Kramer K., Fazzari M., Heller G., Chen L., and Gerald W.L. Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p. J. Mol. Diagn. 2 1 (2000) 37-46